Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFC14A
Source: 0001193125-25-086293
Chunk: 21

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFC14A
Chunk 21
---
 Board’s choice of Mr. McFarlane as the Company’s Chief Executive Officer. Mr. Mangless reiterated his previous suggestion that the Company strengthen its relationship with Dr. Mickle to enhance the LAT (Ligand Activated Therapy) platform pipeline and shared suggestions for corporate governance, including declassifying the Board and increasing the diversity of the Board. Mr. Mangless also noted he was in favor of the Board nominating Dr. Mickle to replace Ms. Favorito at the Annual Meeting, should the Board not increase in size.

On or about October 26, 2024, Mr. Bode called Mr. Mangless to acknowledge Mr. Mangless’ October 23, 2024 email and note that the Company’s management and Board would require time to appropriately review Mr. Mangless’ email before formally responding. Mr. Mangless confirmed via telephone that he was fine with Mr. Bode’s proposed approach.

On October 31, 2024, Dr. Mickle’s consulting arrangement with the Company ended.

<div align='center'>22</div>

During October and November of 2024, Mr. Clifton held several teleconferences with Dr. Mickle via teleconference on several occasions to discuss Dr. Mickle’s potential purchase of laboratory equipment from the Company following the Company’s closure of its laboratory facilities in Iowa and Virginia. The Company ultimately sold the lab equipment to a different third-party buyer.

On November 11, 2024, Mr. Clifton met with Dr. Mickle via teleconference following the conclusion of Dr. Mickle’s consulting arrangement with the Company. Dr. Mickle noted that he was glad to be working on his own and looking forward to working on other projects.

On December 2, 2024, in connection with organizational changes designed to accelerate its transformation into a leading rare disease company, Zevra notified Christal M.M. Mickle, the Company’s then Chief Development Officer, that she would no longer serve in such role, effective as of December 6, 2024.

On December 30, 2024, Rahsaan W. Thompson, the Company’s Chief Legal Officer, Secretary and Compliance officer, sent an introductory email to Mr. Mangless responding to Mr. Mangless’ October 23, 2024 email to Mr. Bode. Mr. Thompson noted that the Nominating and Corporate Governance Committee actively manages Board composition through succession planning, that such committee evaluates the need for the expansion of the Board to align